All In Biotech

Drug Trial Radar · NCT02906020

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant

Last checked: Nov 19, 2026Latest source record: May 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 273 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

273

Actual

Start

Dec 15, 2016

Primary completion

Dec 18, 2020

Study completion May 27, 2021

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Sep 19, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objectives: * Part 1: To determine the safety and tolerability of 4, 8, and 15 milligrams of GZ/SAR402671 (venglustat) administered orally for 4 weeks, as compared to placebo in participants with early-stage Parkinson's disease (PD) carrying a glucocerebrosidase gene (GBA) mutation or other pre-specified variants. * Part 2: To determine the efficacy of GZ/SAR402671 administered orally daily, as compared to placebo in participants with early-stage PD carrying a GBA mutation or other pre-specified variants. Secondary Objectives: Part 1: * To assess the pharmacokinetic (PK) profile of oral dosing of GZ/SAR402671 in plasma when administered in early-stage PD participants carrying a GBA mutation. * To assess the exposure of GZ/SAR402671 in cerebrospinal fluid (CSF) when administered in early-stage PD participants carrying a GBA mutation. Part 2: * To demonstrate overall safety and tolerability of GZ/SAR402671 administered orally for 52 weeks in early-stage PD participants carrying a GBA mutation as compared to placebo. * To assess the pharmacodynamic response to daily oral dosing of GZ/SAR402671 in plasma and CSF as measured by glucosylceramide (GL-1) when administered in early-stage PD participants carrying a GBA mutation over a 52-week period.

Conditions

  • Parkinson's Disease

Interventions

  • venglustat GZ/SAR402671Drug

    Pharmaceutical form: capsule Route of administration: oral

  • PlaceboDrug

    Pharmaceutical form: capsule Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
  2. Part 1: Number of Participants With Abnormal Physical Examination FindingsTime frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
  3. Part 1: Number of Participants With Abnormal Neurological Examination FindingsTime frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
  4. Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: HematologyTime frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
  5. Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function ParametersTime frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
  6. Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal ParametersTime frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
  7. Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic ParametersTime frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
  8. Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes ParametersTime frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
  9. Part 1: Number of Participants With Potentially Clinically Significant Vital Signs AbnormalitiesTime frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
  10. Part 1: Number of Participants With Potentially Clinically Significant Ophthalmological AbnormalitiesTime frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
  11. Part 1: Number of Participants With Potentially Clinically Significant Electrocardiogram AbnormalitiesTime frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
  12. Part 2: Change From Baseline to Week 52 in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II+III Total ScoreTime frame: Baseline to Week 52

Locations

52 sites in 16 countries. Site status is shown where the registry gives one.

  • Investigational Site Number :8400017

    Scottsdale, Arizona

  • Investigational Site Number :8400011

    Scottsdale, Arizona

  • Investigational Site Number :8400004

    La Jolla, California

  • Investigational Site Number :8400019

    Palo Alto, California

  • Investigational Site Number :8400013

    Sunnyvale, California

  • Investigational Site Number :8400015

    New Haven, Connecticut

  • Investigational Site Number :8400008

    Boca Raton, Florida

  • Investigational Site Number :8400016

    Chicago, Illinois

  • Investigational Site Number :8400005

    Chicago, Illinois

  • Investigational Site Number :8400014

    Boston, Massachusetts

  • Investigational Site Number :8400018

    New York, New York

  • Investigational Site Number :8400010

    New York, New York

  • Investigational Site Number :8400001

    New York, New York

  • Investigational Site Number :8400021

    Portland, Oregon

  • Investigational Site Number :8400020

    Portland, Oregon

  • Investigational Site Number :8400009

    Portland, Oregon

  • Investigational Site Number :8400002

    Philadelphia, Pennsylvania

  • Investigational Site Number :8400006

    Fairfax, Virginia

  • Investigational Site Number :8400012

    Kirkland, Washington

  • Investigational Site Number :0400001

    Innsbruck, Austria

  • Investigational Site Number :1240003

    Vancouver, British Columbia, Canada

  • Investigational Site Number :1240002

    Ottawa, Ontario, Canada

  • Investigational Site Number :1240001

    Montreal, Quebec, Canada

  • Investigational Site Number :2500001

    Paris, France

  • Investigational Site Number :2760002

    Kiel, Germany

  • Investigational Site Number :2760001

    Tübingen, Germany

  • Investigational Site Number :3000002

    Larissa, Greece

  • Investigational Site Number :3760002

    Haifa, Israel

  • Investigational Site Number :3760003

    Petah Tikva, Israel

  • Investigational Site Number :3760001

    Tel Aviv, Israel

  • Investigational Site Number :3760004

    Tel HaShomer, Israel

  • Investigational Site Number :3800001

    Catanzaro, Italy

  • Investigational Site Number :3800004

    Milan, Italy

  • Investigational Site Number :3800003

    Pavia, Italy

  • Investigational Site Number :3800002

    Salerno, Italy

  • Investigational Site Number :3800006

    Rozzano, Milano, Italy

  • Investigational Site Number :3920005

    Nagoya, Aichi-ken, Japan

  • Investigational Site Number :3920002

    Kyoto, Kyoto, Japan

  • Investigational Site Number :3920004

    Osaka, Osaka, Japan

  • Investigational Site Number :3920001

    Bunkyo-ku, Tokyo, Japan

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.